newsfilter
← Latest News
Business Wire·

CytRx Comments on Orphazyme's Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C

CytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ:ORPH) ("Orphazyme") recently anno